Citations

Clear

8 citation(s) found for "Shin, Jennifer".

Deep Brain Stimulation: Past, Present, and Future
Choo, Minhye, Hong, Lydia S., Tang-Cabrera, Jennifer , Shin, Jennifer, Shin, Hojin , Park, SungMin, Lee, Kendall H. , Shin, Jee Won , Oh, Yoonbae , Scheitler, Kristen M. , Blaha, Charles D.

Mayo Clinic

IEEE Transactions on Biomedical Engineering | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1109/tbme.2026.3686882 | PMID 42024924 Get It

Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator
Shin, Jee Won Jennifer, Siontis, Konstantinos C. , Killu, Ammar M. , Giudicessi, John R. , Ackerman, Michael J. , Deshmukh, Abhishek , Kowlgi, Gurukripa N. , Madhavan, Malini , McLeod, Christopher J., Asirvatham, Samuel J. , Munoz, Freddy Del‐Carpio , Shin, Jee Won , Ezzeddine, Fatima , Siontis, Konstantinos C , Killu, Ammar M , Giudicessi, J R , Ackerman, Michael J , Deshmukh, Abhishek J , Kowlgi, Narayan G , Madhavan, Malini , Asirvatham, Samuel J , Del-Carpio Munoz, Freddy , Ezzeddine, Fatima M. , Shin, Jee Won Jennifer, McLeod, Christopher J.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | March 18, 2025 | Volume: 36 | Issue: 5 | Pages: 1014-1021

10.1111/jce.16612 | PMID 40098314 Get It

ABSTRACT Background Mitral annular disjunction (MAD) carries an increased risk of complex ventricular arrhythmias, which can lead to sudden cardiac death. Many of these patients undergo implantable cardioverter defibrillator (ICD) implantation, but their ICD outcomes are not known. Objective The aim of this study was to assess the outcomes of ICD implantation and the predictors of appropriate ICD therapies in patients with MAD. Methods The study included patients with MAD who underwent ICD implantation. Clinical, electrocardiographic, cardiac imaging, and device therapy data were collected. Results Forty‐nine patients with MAD and ICD were included. Median age was 49 (21) years, and 29 (59%) were female. 13 (27%) patients underwent ICD implantation for primary prevention and 36 (73%) patients for secondary prevention. Over a median follow‐up of 27.3 (35.3) months, 23 (47%) patients received ICD therapies. 18 (37%) patients had appropriate ICD therapies, and 5 (10%) patients had inappropriate ICD shocks. Median time to first appropriate therapy was 22.3 (63.3) months. In patients with a secondary prevention ICD indication, the rate of appropriate ICD therapies was 44%, while in patients with a primary prevention ICD indication, it was 15%. Among patients with appropriate ICD therapies, the first therapies were delivered for monomorphic ventricular tachycardia (VT) in 7 (39%) patients and polymorphic VT or ventricular fibrillation (VF) in 11 (61%) patients. Patients with appropriate ICD therapies were more likely to have a history of SCA ( p = 0.003) and/or low left ventricular ejection fraction (LVEF) ( p = 0.022) before ICD implantation as compared to patients without appropriate ICD therapies. Conclusions In our cohort of patients with MAD and ICD, appropriate ICD therapies were common. Most appropriate ICD therapies were delivered for polymorphic VT or VF. Larger studies are needed to elucidate the mechanisms of VAs and refine risk stratification in MAD.
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
Shonka, David C. , Geiger, J.L. , Park, Jong Chul , Jasim, Sina , Ahmed, Amr H. Abdelhamid , Bible, Keith C. , Brose, Marcia S. , Dabekaussen, Kirsten F. A. A. , Dias‐Santagata, Dora , Ghossein, Ronald , Gopal, Raj K., Ryder, Mabel , Sherman, Eric J. , Shin, Jennifer J. , Stack, Brendan C. , Tuttle, R. Michael , Wirth, Lori J. , Zafereo, Mark , Park, Jong C , Abdelhamid Ahmed, Amr H , Cabanillas, Maria E , Davies, Louise , Ryder, Mabel M, Ryder, Mabel , Ho, Alan L. , Chintakuntlawar, Ashish V. , Seetharamu, Nagashree , Cabanillas, Maria E. , Fagin, James A. , Faquin, William C , Miyauchi, Akira , Nikiforov, Yuri E. , Ringel, Matthew D. , Robinson, Bruce , Sadow, Peter M. , Randolph, Gregory William

Mayo Clinic

Head & Neck | March 11, 2022 | Volume: 44 | Issue: 6 | Pages: 1277-1300

10.1002/hed.27025 | PMID 35274388 Get It

AbstractBackgroundThe development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence‐based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.MethodsAn expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.ResultsA review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.ConclusionsWith the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS‐ES) on Pediatric Benign and Malignant Thyroid Surgery
Stack, Brendan C. , Twining, Christine, Rastatter, Jeff C., Diercks, Gillian R. , Kazahaya, Ken , Rivkees, Scott A. , Sheyn, Tony, Shin, Jennifer J. , Smith, Jessica R. , Thompson, Geoffrey B. , Viswanathan, Pushpa, Brooks, Jennifer A. , Angelos, Peter , Baloch, Zubair , Faquin, William C , Wassner, Ari J , Randolph, Gregory William

Mayo Clinic

Head & Neck | January 2, 2021 | Volume: 43 | Issue: 4 | Pages: 1027-1042

10.1002/hed.26586 | PMID 33386657 Get It

AbstractObjectivesTo provide a clinical disease state review of recent relevant literature and to generate expert consensus statements regarding the breadth of pediatric thyroid cancer diagnosis and care, with an emphasis on thyroid surgery. To generate expert statements to educate pediatric practitioners on the state‐of‐the‐art practices and the value of surgical experience in the management of this unusual and challenging disease in children.MethodsA literature search was conducted and statements were constructed and subjected to a modified Delphi process to measure the consensus of the expert author panel. The wording of statements, voting tabulation, and statistical analysis were overseen by a Delphi expert (J.J.S.).ResultsTwenty‐five consensus statements were created and subjected to a modified Delphi analysis to measure the strength of consensus of the expert author panel. All statements reached a level of consensus, and the majority of statements reached the highest level of consensus.ConclusionPediatric thyroid cancer has many unique nuances, such as bulky cervical adenopathy on presentation, an increased incidence of diffuse sclerosing variant, and a longer potential lifespan to endure potential complications from treatment. Complications can be a burden to parents and patients alike. We suggest that optimal outcomes and decreased morbidity will come from the use of advanced imaging, diagnostic testing, and neural monitoring of patients treated at high‐volume centers by high‐volume surgeons.
Improving Recognition, Diagnosis, and Management Of Heparin Induced Thrombocytopenia By Implementing a Computer-Based Clinical Decision Support System
Pruthi, Rajiv K. , Shin, Jennifer S, Dobie, Mark W, Schaefer, Jordan K. , Caraballo, Pedro J.

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 2966-2966

10.1182/blood.v122.21.2966.2966 Get It

Abstract Introduction Heparin induced thrombocytopenia (HIT) is often not considered as a potential etiology of thrombocytopenia. The gradual 5 to 14 day decline in platelet count (PC) may not be easily recognized by busy clinicians. The life-threatening complications of HIT are potentially preventable with prompt recognition and management. Implementation of computer-based clinical decision support systems (CDSS) may aid in addressing these issues. Such systems have shown promise in increasing provider recognition, appropriate testing, and management of a variety of conditions. Methods We developed, implemented and evaluated a CDSS designed to identify patients at risk for HIT. The CDSS was integrated into the electronic medical record (Centricity Enterprise, GE) at Mayo Clinic Rochester. The CDSS identified inpatients with recent or active use of heparin medications, who experienced a 50% PC drop. For such patients, the system generated an electronic message alerting their care team of the 50% PC drop and asked them to consider the possibility of HIT. A link to a website with recommendations for the diagnosis and management of HIT was included with the alert. Providers were encouraged to assess for HIT using the 4Ts Score and, if indicated, the anti-heparin/platelet factor 4 (PF4) antibody assay. We performed a retrospective chart review of consecutive patients identified by the system and equal number of randomly generated controls that did not trigger alerts. The accuracy of the algorithm was assessed and errors were analyzed for clinical significance. Patient risk of HIT was evaluated by using the 4Ts Score and the HIT Expert Probability (HEP) Score. Alert effect was classified as: Results Over the study period, 2,785 patients had a total of 37,060 PC (13.31 PC/patient) and the CDSS triggered a total of 124 alerts. About 10% of alerted clinicians reviewed the website with recommendations on the management of HIT. A total of 117 patients generating alerts were compared to 124 controls. Demographics between the two groups were similar. The CDSS had a 95% sensitivity for accurately detecting a 50% platelet drop for inpatients on heparin. The specificity was 74%. The Objective alert effect was found in 21% of the cases (16% of providers changed their management and 5% documented that HIT was felt to be unlikely). The most common actions taken after receiving the alert were obtaining a HIT antibody assay, withholding heparin, consulting a subspecialty service, and/or changing anticoagulants. The Probable alert effect was 14% of the cases. HIT had been considered before the alert was sent in 11% of patients. Alert effect was classified as None for the remaining 54% of patients. Anti-heparin/PF4 testing for HIT was ordered for 25% of the intervention patients compared to 3% of controls. For the intervention group, PF4 was negative for 86% of tested patients, equivocal for 10%, and positive in 3%. All PF4 tests were negative in the control group. 4Ts score was greater than or equal to 4 in 38% of patients and averaged 3.1 (range 7 to 0). HEP score averaged 4 (range 14 to -4). Risk calculations showed a trend to higher risk with therapeutic heparin compared to prophylactic heparin preparations. HIT risk scores were comparable by admitting service and diagnosis. Conclusions Our CDSS successfully identified upwards of 95% of inpatients at risk for HIT. However, approximately 26% of the alerts were false positives. Only a small proportion of clinicians accessed the website with recommendations for the diagnosis and management of HIT but patients with a suspected HIT were managed appropriately. Of the patients triggering a HIT alert, 38% had an intermediate or high clinical probability of HIT based on the 4Ts Score that would be an indication for further testing. This result highlights the success of the CDSS in identifying patients needing further evaluation but also the difficulties of a computer-based CDSS in representing all the important clinical criteria for the diagnosis of HIT. Disclosures: No relevant conflicts of interest to declare.
American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules
Meltzer, Charles , Irish, Jonathan C. , Busaidy, Naifa L. , Dwojak, Sunshine , Haugen, Bryan R. , Harrell, R. Mack, Haymart, Megan R. , McIver, Bryan, Monteiro, Eric, Odell, Michael , Scharpf, Joseph , Shaha, Ashok R. , Shin, Jennifer J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Urken, Mark L. , Wiseman, Sam M. , Meltzer, Charles J , Angelos, Peter , Davies, Louise , Ferris, Robert L. , Mechanick, Jeffrey I. , Morris, John C., Morris, Luc G T , Shonka, David C. , Wong, Richard J. , Randolph, Gregory William

Mayo Clinic

Head & Neck | December 18, 2018 | Volume: 41 | Issue: 4 | Pages: 843-856

10.1002/hed.25526 | PMID 30561068 Get It

AbstractBackgroundCare for patients with thyroid nodules is complex and multidisciplinary, and research demonstrates variation in care. The objective was to develop clinical guidelines and quality metrics to reduce unwarranted variation and improve quality.MethodsMultidisciplinary expert consensus and modified Delphi approach. Source documents were workflow algorithms from Kaiser Permanente Northern California and Cancer Care of Ontario based on the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.ResultsA consensus‐based, unified preoperative, perioperative, and postoperative workflow was developed for North American use. Twenty‐one panelists achieved consensus on 16 statements about workflow‐embedded process and outcomes metrics addressing safety, access, appropriateness, efficiency, effectiveness, and patient centeredness of care.ConclusionA panel of Canadian and United States experts achieved consensus on workflows and quality metric statements to help reduce unwarranted variation in care, improving overall quality of care for patients diagnosed with thyroid nodules.
Education on, Exposure to, and Management of Vascular Anomalies During Otolaryngology Residency and Pediatric Otolaryngology Fellowship
Jabbour, Noel , Balakrishnan, Karthik , Darrow, David H., Elluru, Ravindhra G., Grimmer, J. Fredrik , Richter, Gresham T. , Shin, Jennifer J. , Chun, Robert H. , Bauman, Nancy M. , Perkins, Jonathan A. , Balakrishnan, Karthik

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 28, 2016 | Volume: 142 | Issue: 7 | Pages: 648

10.1001/jamaoto.2016.0605 | PMID 27124736 Get It

Standardized Outcome and Reporting Measures in Pediatric Head and Neck Lymphatic Malformations
Balakrishnan, Karthik , Bauman, Nancy M. , Darrow, David H., Grimmer, J. Fredrik , Richter, Gresham T. , Shin, Jennifer J. , Shivaram, Giridhar M. , Sidell, Douglas R. , Elluru, Ravindhra G., Sidell, Douglas R. , Chun, Robert H. , Perkins, Jonathan A. , Sidell, Douglas R , Balakrishnan, Karthik

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 1, 2015 | Volume: 152 | Issue: 5 | Pages: 948-953

10.1177/0194599815577602 | PMID 25829389 Get It

ObjectiveTo develop general and site‐specific treatment effect and outcome measures to standardize the reporting of head and neck lymphatic malformation (HNLM) treatments.Study DesignConsensus statement/expert opinion.SettingMultiple tertiary academic institutions.Subjects and MethodsThe modified Delphi method is an iterative process of collecting expert opinions, refining opinions through discussion and feedback, statistically aggregating opinions, and using these aggregates to generate consensus opinion in the absence of other data. The modified Delphi method was used by a multi‐institutional group of otolaryngology and interventional radiology experts in the field of vascular anomalies to formulate a list of recommended reporting outcomes for the study and treatment of head and neck lymphatic malformations.ResultsThrough 3 rounds of iteration, 10 expert panelists refined 98 proposed outcome measures and 9 outcome categories to a final consensus set of 50 recommended outcome measures in 3 global categories (general, demographics, and treatment complications) and 5 site‐specific categories (orbit, oral cavity, pharynx, larynx, and neck).ConclusionsWe propose the first consensus set of standardized reporting measures for clinical and treatment outcomes in studies of HNLMs. Consistent outcome measures across future studies will facilitate comparison of treatment options and allow systematic review. We hope that these guidelines facilitate the design and reporting of subsequent HNLM studies.